Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022192944 - COMBINATION THERAPY FOR TREATMENT OF ALS

Publication Number WO/2022/192944
Publication Date 22.09.2022
International Application No. PCT/AU2022/050222
International Filing Date 15.03.2022
IPC
A61K 31/436 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
436the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/341 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/496 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/519 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants
  • GENIEUS GENOMICS PTY LTD [AU]/[AU]
Inventors
  • BRENNAN, Samuel
  • SU, Zheng
  • WEST, Phillip
  • KEON, Matthew
Agents
  • FB RICE PTY LTD
Priority Data
202190074215.03.2021AU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION THERAPY FOR TREATMENT OF ALS
(FR) POLYTHÉRAPIE POUR LE TRAITEMENT DE LA SLA
Abstract
(EN) The present disclosure relates to therapeutic methods, and composition thereof, comprising a mTOR pathway inhibitor, and an inhibitor of at least one tyrosine kinase selected from c-Kit, Lyn, Fyn, CSF1R and PDGFR; and further comprising at least one of an unfolded protein response pathway inhibitor, or an inflammasome inhibitor, for treating neurodegenerative diseases, disorders or conditions, such as amyotrophic lateral sclerosis (ALS). Specifically, the present disclosure relates to the administration of Rapamycin and Mastinib, in combination with either MCC950 or GSK2606414 for the treatment of ALS.
(FR) La présente invention concerne des méthodes thérapeutiques, et une composition associée, comprenant un inhibiteur de la voie mTOR, et un inhibiteur d'au moins une tyrosine kinase choisie parmi c-Kit, Lyn, Fyn, CSF1R et PDGFR ; et comprenant en outre au moins l'un d'un inhibiteur de la voie de réponse aux protéines non repliées, ou d'un inhibiteur de l'inflammasome, pour le traitement de maladies, troubles ou états neurodégénératifs, tels que la sclérose latérale amyotrophique (SLA). Spécifiquement, la présente invention concerne l'administration de Rapamycine et de Mastinib, en combinaison avec soit MCC950, soit GSK2606414 pour le traitement de la SLA.
Latest bibliographic data on file with the International Bureau